
Explore how the FDA regulates drugs, biologics, cosmetics, and devices, covering IND and NDA/ANDA/BLA pathways, safety standards, and the 21 CFR framework.
Explore how scientists study diseases across CNS, neural, and cardiovascular areas, model molecules, and advance candidates from combinatorial libraries through pharmacology and toxicology testing to IND and NDA approvals.
Define a new drug under the Federal Food, Drug, and Cosmetic Act, including four-part criteria and entities. Distinguish drugs from devices by chemistry and metabolism; note otc monographs and anda.
Learn how non-clinical testing in animals establishes safety for biologics, covering pharmacodynamics, pharmacokinetics, adme, and toxicology safety studies from acute to chronic, including reproductive, genotoxicity, and carcinogenicity.
Explore how nonclinical studies are regulated under good laboratory practice to ensure data integrity, risk assessment for human trials, and FDA-required GLP elements: organization, qualification, controls, and documentation.
Navigate the IND process with FDA meetings that focus on safety data, toxicology, and CMC, guiding phase one through phase three pivotal trials toward NDA approval.
Learn how the FDA's FD&C act governs IND and NDA processes, including nonclinical, clinical, and CMC data, and how amendments and forms 1571 and 1572 support investigator-driven interstate clinical trials.
Learn how the institutional review board protects participant safety, rights, and welfare in IND trials, and how informed consent forms clearly explain risks, benefits, and participation rights.
Explore the FDA form 1571, its IND submission structure, and the required information for sponsors to initiate clinical trials of drugs or biologics with the FDA.
CDER reviews INDs to assess safety and effectiveness, accuracy of labeling, and manufacturing standards, coordinating multidisciplinary expert reviews to decide if a clinical trial may proceed or must hold.
Learn how to update an IND with protocol amendments and information amendments, submit the 1571/1572 forms, assign serial numbers, and prepare annual safety reports for FDA.
Developing New Drugs
Unlock new job opportunities and advance your career in the pharmaceutical industry by gaining critical skills in regulatory affairs, drug development, and U.S. FDA processes.
This course provides in-depth knowledge of the Investigational New Drug (IND) application, U.S. FDA regulatory guidelines, non-clinical studies, and the complete process of bringing a drug to market. Whether you're a student, researcher, or working professional, this is your chance to upgrade your profile with job-ready skills in the high-demand regulatory field.
This course will give you insights on Investigational New Drug, IND Review, Basic for INDA, USFDA regulations, Nonclinical study overview, Updating INDA
Before a drug can be tested in people, the drug company or sponsor performs laboratory and animal tests to discover how the drug works and whether it's likely to be safe and work well in humans. Next, a series of tests in people is begun to determine whether the drug is safe when used to treat a disease and whether it provides a real health benefit.
Drug development and approval process:
The mission of FDA's Center for Drug Evaluation and Research (CDER) is to ensure that drugs marketed in this country are safe and effective. CDER does not test drugs, although the Center's Office of Testing and Research does conduct limited research in the areas of drug quality, safety, and effectiveness.
Some companies submit a new drug application (NDA) to introduce a new drug product into the U.S. Market. It is the responsibility of the company seeking to market a drug to test it and submit evidence that it is safe and effective. A team of CDER physicians, statisticians, chemists, pharmacologists, and other scientists reviews the sponsor's NDA containing the data and proposed labeling.
What You’ll Learn
The Drug Development Process from lab to market
Investigational New Drug (IND) application & review procedures
Basics of INDA (Investigational New Drug Application)
Overview of non-clinical (preclinical) studies
Key USFDA regulations you must know
How CDER (Center for Drug Evaluation and Research) evaluates drug safety and efficacy
Course Benefits
Gain job-oriented skills in regulatory affairs
Improve chances of selection in pharma interviews
Add a valuable skill to your professional resume
Stay updated with the latest developments in drug regulations
Learn directly applicable knowledge for roles in FDA submissions and approvals
Course Format
100% online and self-paced
No prerequisites required – just curiosity and a background in science or healthcare
Certificate of Completion provided
Lifetime access to course content
By the End of This Course, You Will:
Understand how new drugs are developed and approved
Be familiar with the regulatory frameworks of the U.S. FDA
Be ready to apply for roles in research and regulatory departments
Enhance your profile with in-demand pharmaceutical skills
Prerequisites: No prerequisites required, only need curiosity towards learning and science background.
Achivements after course:
Certificate of completion.
Add on skill.
You can update your professional profile.
New job opportunities in research.
Life time access to course.
Upgrade your skills and knowledge in clinical research.